SAM
ARCT icon

Shell Asset Management’s Arcturus Therapeutics ARCT Stock Holding History

Shell Asset Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-5,282
Closed -$69K – 1158
2025
Q2 		$69K Sell
5,282
-6,767
-56% -$80K ﹤0.01% 1080
2025
Q1 		$128K Sell
12,049
-505
-4% -$8.02K 0.01% 948
2024
Q4 		$213K Hold
12,554
– – 0.01% 817
2024
Q3 		$291K Buy
+12,554
New +$269K 0.01% 702
2024
Q1 		$313K Sell
12,869
-3,905
-23% -$138K 0.01% 665
2023
Q4 		$529K Sell
16,774
-5,030
-23% -$120K 0.02% 496
2023
Q3 		$557K Sell
21,804
-377
-2% -$11.6K 0.02% 518
2023
Q2 		$636K Sell
22,181
-7,517
-25% -$205K 0.03% 496
2023
Q1 		$712K Buy
29,698
+13,843
+87% +$248K 0.03% 449
2022
Q4 		$269K Buy
+15,855
New +$276K 0.01% 819
2020
Q4 		– Sell
-1,510
Closed -$65K – 1435
2020
Q3 		$65K Hold
1,510
– – ﹤0.01% 1236
2020
Q2 		$71K Buy
+1,510
New +$52K ﹤0.01% 1197

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Shell Asset Management's ARCT Position: Q3 2025 in Review

Shell Asset Management sold out of Arcturus Therapeutics (ARCT) in Q3 2025, closing a stake of 5,282 shares — an estimated $69K sold.

Shell Asset Management first reported a position in ARCT in Q2 2020 and held it in 12 quarters. The position peaked at $712K in Q1 2023. 136 funds tracked by Wall St. Rank hold ARCT as of Q3 2025.

  • Shell Asset Management reported no remaining Arcturus Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Shell Asset Management sold 5,282 Arcturus Therapeutics shares in Q3 2025, an estimated $69K.
  • Shell Asset Management first reported a position in Arcturus Therapeutics in Q2 2020 and held it in 12 quarters.
  • Shell Asset Management's Arcturus Therapeutics position peaked at $712K in Q1 2023.
  • 136 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.